Abstract
Introduction: Continuous renal replacement therapy (CRRT) is one of the most critical interventions in the intensive care unit, and anticoagulation is essential to ensure its efficacy. Regional citrate anticoagulation (RCA) has been widely adopted in clinical practice due to its reduced risk of bleeding complications. However, the suitability of RCA for CRRT in patients with hyperlactatemia remains controversial. Methods: This study aimed to evaluate the efficacy and safety of different anticoagulation strategies (heparin systemic anticoagulation, RCA, and no anticoagulation) during CRRT in critically ill patients with hyperlactatemia. Using a retrospective cohort design, we analyzed clinical data from the MIMIC-IV v3.0 database, employing propensity score matching and multivariable Cox regression models to adjust for confounding factors. Results: Our findings demonstrated that compared to the no-anticoagulation group, the citrate group exhibited significantly lower 28-day, 60-day, and 90-day mortality risks, with hazard ratios (HRs) of 0.623, 0.650, and 0.657, respectively. In contrast, the heparin group showed a significant reduction only in 28-day mortality risk (HR = 0.625). These results were further validated in the matched cohort, indicating that RCA significantly improves clinical outcomes and reduces mortality in hyperlactatemia patients requiring CRRT. Conclusion: In summary, our study indicates that citrate anticoagulation significantly improves the prognosis of CRRT in patients with hyperlactatemia, suggesting its potential as a preferred anticoagulation strategy in this clinical setting.
Journal Section:
Hemodialysis
References
1.
Prowle
JR
, Bellomo
R
. Continuous renal replacement therapy: recent advances and future research
. Nat Rev Nephrol
. 2010
;6
(9
):521
–9
. 2.
3.
Link
A
, Klingele
M
, Speer
T
, Rbah
R
, Pöss
J
, Lerner-Gräber
A
, et al. Total-to-ionized calcium ratio predicts mortality in continuous renal replacement therapy with citrate anticoagulation in critically ill patients
. Crit Care
. 2012
;16
(3
):R97
. 4.
Bai
M
, Zhou
M
, He
L
, Ma
F
, Li
Y
, Yu
Y
, et al. Citrate versus heparin anticoagulation for continuous renal replacement therapy: an updated meta-analysis of RCTs
. Intensive Care Med
. 2015
;41
(12
):2098
–110
. 5.
Morabito
S
, Guzzo
I
, Solazzo
A
, Muzi
L
, Luciani
R
, Pierucci
A
. Continuous renal replacement therapies: anticoagulation in the critically ill at high risk of bleeding
. J Nephrol
. 2003
;16
(4
):566
–71
.6.
Haas
SA
, Lange
T
, Saugel
B
, Petzoldt
M
, Fuhrmann
V
, Metschke
M
, et al. Severe hyperlactatemia, lactate clearance and mortality in unselected critically ill patients
. Intensive Care Med
. 2016
;42
(2
):202
–10
. 7.
Gomez
H
, Kellum
JA
. Lactate in sepsis
. JAMA
. 2015
;313
(2
):194
–5
. 8.
Li
L
, Bai
M
, Zhang
W
, Zhao
L
, Yu
Y
, Sun
S
. Regional citrate anticoagulation versus low molecular weight heparin for CRRT in hyperlactatemia patients: a retrospective case-control study
. Int J Artif Organs
. 2022
;45
(4
):343
–50
. 9.
Li
L
, Bai
M
, Yu
Y
, Li
Y
, Zhao
L
, Sun
S
. Regional citrate anticoagulation vs no‐anticoagulation for CRRT in hyperlactatemia patients with increased bleeding risk: a retrospective cohort study
. Semin Dial
. 2021
;34
(3
):209
–17
. 10.
Khadzhynov
D
, Schelter
C
, Lieker
I
, Mika
A
, Staeck
O
, Neumayer
HH
, et al. Incidence and outcome of metabolic disarrangements consistent with citrate accumulation in critically ill patients undergoing continuous venovenous hemodialysis with regional citrate anticoagulation
. J Crit Care
. 2014
;29
(2
):265
–71
. 11.
Tan
J-N
, Haroon
SWP
, Mukhopadhyay
A
, Lau
T
, Murali
TM
, Phua
J
, et al. Hyperlactatemia predicts citrate intolerance with regional citrate anticoagulation during continuous renal replacement therapy
. J Intensive Care Med
. 2019
;34
(5
):418
–25
. 12.
Zhang
Z
, Hongying
N
. Efficacy and safety of regional citrate anticoagulation in critically ill patients undergoing continuous renal replacement therapy
. Intensive Care Med
. 2012
;38
(1
):20
–8
. 13.
Wu
M-Y
, Hsu
Y-H
, Bai
C-H
, Lin
Y-F
, Wu
C-H
, Tam
K-W
. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a meta-analysis of randomized controlled trials
. Am J Kidney Dis
. 2012
;59
(6
):810
–8
. 14.
Johnson
AEW
, Bulgarelli
L
, Shen
L
, Gayles
A
, Shammout
A
, Horng
S
, et al. MIMIC-IV, a freely accessible electronic health record dataset
. Sci Data
. 2023
;10
(1
):1
. 15.
Zhang
L
, Wang
Z
, Xu
F
, Han
D
, Li
S
, Yin
H
, et al. Effects of stress hyperglycemia on short-term prognosis of patients without diabetes mellitus in coronary care unit
. Front Cardiovasc Med
. 2021
;8
:683932
. 16.
Gershengorn
HB
, Stelfox
HT
, Niven
DJ
, Wunsch
H
. Association of premorbid blood pressure with vasopressor infusion duration in patients with shock
. Am J Respir Crit Care Med
. 2020
;202
(1
):91
–9
. 17.
Ou
S-Y
, Lee
Y-J
, Chou
Y-M
, Sun
G-C
, Chia
Y-Y
. Hyperlactatemia is associated with increased risks of long-term mortality and major adverse cardiovascular events in sepsis survivors
. Infect Dis
. 2023
;55
(8
):576
–84
. 18.
Wardi
G
, Brice
J
, Correia
M
, Liu
D
, Self
M
, Tainter
C
. Demystifying lactate in the emergency department
. Ann Emerg Med
. 2020
;75
(2
):287
–98
. 19.
Renew
JR
, Barbara
DW
, Hyder
JA
, Dearani
JA
, Rivera
M
, Pulido
JN
. Frequency and outcomes of severe hyperlactatemia after elective cardiac surgery
. J Thorac Cardiovasc Surg
. 2016
;151
(3
):825
–30
. 20.
Khadzhynov
D
, Dahlinger
A
, Schelter
C
, Peters
H
, Kindgen-Milles
D
, Budde
K
, et al. Hyperlactatemia, lactate kinetics and prediction of citrate accumulation in critically ill patients undergoing continuous renal replacement therapy with regional citrate anticoagulation
. Crit Care Med
. 2017
;45
(9
):e941
–6
. 21.
Tang
S
, Yu
Y
, Tang
S
, Liu
T
, Wu
H
, Liu
Y
, et al. Regional citrate anticoagulation versus LMWH anticoagulation for CRRT in liver failure patients without increased bleeding risk
. Int J Artif Organs
. 2024
;47
(10
):756
–64
. 22.
Soltysiak
J
, Warzywoda
A
, Kociński
B
, Ostalska-Nowicka
D
, Benedyk
A
, Silska-Dittmar
M
, et al. Citrate anticoagulation for continuous renal replacement therapy in small children
. Pediatr Nephrol
. 2014
;29
(3
):469
–75
. 23.
Windeløv
NA
, Ostrowski
SR
, Perner
A
, Johansson
PI
. Transfusion requirements and clinical outcome in intensive care patients receiving continuous renal replacement therapy: comparison of prostacyclin vs. heparin prefilter administration
. Blood Coagul Fibrinolysis
. 2010
;21
(5
):414
–9
. 24.
Kaewdoungtien
P
, Tachaboon
S
, Kangsumrith
N
, Srisawat
N
. Immunomodulation effect of regional citrate anticoagulation in acute kidney injury requiring renal replacement therapy
. Blood Purif
. 2023
;52
(5
):474
–82
. 25.
Liu
S-Y
, Xu
S-Y
, Yin
L
, Yang
T
, Jin
K
, Zhang
Q-B
, et al. Management of regional citrate anticoagulation for continuous renal replacement therapy: guideline recommendations from Chinese emergency medical doctor consensus
. Mil Med Res
. 2023
;10
(1
):23
. 26.
Arepally
GM
, Cines
DB
. Pathogenesis of heparin-induced thrombocytopenia
. Transl Res
. 2020
;225
:131
–40
. 27.
Vecchio
C
, Frisinghelli
A
. Topically applied heparins for the treatment of vascular disorders: a comprehensive review
. Clin Drug Investig
. 2008
;28
(10
):603
–14
. 28.
Bauman
MMJ
, Naylor
RM
, Santilli
AR
, Wijdicks
EF
. Delayed-onset heparin-induced thrombocytopenia with cerebral venous sinus thrombosis following total knee arthroplasty: case report
. Neurohospitalist
. 2022
;12
(2
):328
–31
. 29.
Cosmi
B
, Legnani
C
, Cini
M
, Borgese
L
, Sartori
M
, Palareti
G
. Incidence and clinical outcomes of heparin-induced thrombocytopenia: 11 year experience in a tertiary care university hospital
. Intern Emerg Med
. 2023
;18
(7
):1971
–80
. 30.
Warkentin
TE
, Greinacher
A
. Laboratory testing for heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia antibodies: a narrative review
. Semin Thromb Hemost
. 2023
;49
(6
):621
–33
. 31.
Bryland
A
, Wieslander
A
, Carlsson
O
, Hellmark
T
, Godaly
G
. Citrate treatment reduces endothelial death and inflammation under hyperglycaemic conditions
. Diab Vasc Dis Res
. 2012
;9
(1
):42
–51
. 32.
Crenshaw
BL
, McMartin
KE
. Calcium oxalate monohydrate is associated with endothelial cell toxicity but not with reactive oxygen species accumulation
. Cardiovasc Toxicol
. 2020
;20
(6
):593
–603
. 33.
Dellepiane
S
, Medica
D
, Guarena
C
, Musso
T
, Quercia
AD
, Leonardi
G
, et al. Citrate anion improves chronic dialysis efficacy, reduces systemic inflammation and prevents Chemerin-mediated microvascular injury
. Sci Rep
. 2019
;9
(1
):10622
. 34.
Dhondt
A
, Vanholder
R
, Tielemans
C
, Glorieux
G
, Waterloos
MA
, De Smet
R
, et al. Effect of regional citrate anticoagulation on leukopenia, complement activation, and expression of leukocyte surface molecules during hemodialysis with unmodified cellulose membranes
. Nephron
. 2000
;85
(4
):334
–42
. © 2025 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.
